Gastrointestinal Medicines · LP-077
Domperidone Tablets
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-077Gastrointestinal Medicines
- Generic identity
- DomperidoneTablet
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-077
- Generic identity
- Domperidone
- Presentation
- Tablet
- Catalogue strength
- 10 mg
- Catalogue pack
- Blister 10 x 10 tablets
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Generic identity: domperidone.
- Dosage form: tablet.
- Catalogue strength: 10 mg.
- Catalogue pack: blister 10 × 10 tablets.
Layer 02 · Unresolved product-specific fields
- Approved indication, age/weight eligibility and treatment duration.
- Current cardiac/QT, interaction and other contraindications/warnings for the intended market.
- Tablet formulation, score/divisibility and excipients.
- Storage, shelf life, registration, manufacturing route and supply status.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 10 mg | Tablet | — | Blister 10 × 10 tablets | Use restrictions and contraindications require the exact current authorised label; the catalogue cannot supply them. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Domperidone is an antiemetic that affects dopamine signaling and gastrointestinal movement. Its use is limited by potentially serious effects on heart rhythm, and national authorizations differ. It should not be presented as a routine pediatric nausea medicine simply because a liquid exists. This page provides ingredient education for professional review; it does not establish an approved Luang Pharma indication, pediatric age range, or suitability for a particular patient.
Clinical context and therapeutic role
Before considering an antiemetic, the cause of vomiting and any dehydration, obstruction or other serious illness should be assessed. UK regulators removed the indication in children younger than twelve following evidence of lack of efficacy in that population; other countries have their own restrictions. Selection requires review of the current local authorization, cardiac history, liver function and interacting medicines. Persistent vomiting or inability to keep fluids down warrants clinical attention.
Selected safety context
Domperidone can prolong the QT interval and cause serious ventricular arrhythmias. Risk assessment includes existing rhythm disorders, significant electrolyte abnormalities, heart failure and interacting QT-prolonging medicines or strong metabolic inhibitors. Significant hepatic impairment and gastrointestinal bleeding, obstruction or perforation may make use inappropriate. Palpitations, fainting or collapse require urgent assessment. Dry mouth can occur. Age restrictions and treatment limits must follow the current authorized local label and professional judgment.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
The catalogue describes a tablet presentation. The exact salt, coating, score line and release characteristics need confirmation from the authorized product information. A milligram strength identifies ingredient quantity; it does not establish whether a tablet may be split, crushed or exchanged for another formulation.
Keep the product in its labeled packaging so the batch, expiry and instructions remain identifiable. Follow the actual label for storage conditions and disposal. Do not use a damaged or unidentified tablet, and keep all medicines securely out of children’s reach.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
A clinician or pharmacist should assess the cause of symptoms, alarm features and interacting medicines before selecting treatment. Persistent or recurrent symptoms require review. The exact authorized label determines formulation-specific administration and local restrictions.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Approved label/leaflet for the exact jurisdiction.
Finished-product specification and formula.
Pack/SKU documentation.
Registration/market-status and supply evidence.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B07a checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| MHRA: Domperidone — new contraindication in patients with phaeochromocytomaArchived source classification: government medicine safety update | Source revision recorded: 21 July 2026; Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval or evidence of equivalence. |
| MHRA: Domperidone for nausea and vomiting — lack of efficacy in childrenArchived source classification: government medicine safety update | Source revision recorded: 16 December 2019; Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval or evidence of equivalence. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-077.
Professional enquiries
Request product-specific evidence for LP-077.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.